Fate Therapeutics(NASDAQ) FATE

Current Price$2.58

Market Cap$329.86M

Since IPO (2013)-57%

5 Year-97%

1 Year+146%

1 Month+35%

Fate Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 2.83	2026-07-21

Fate Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-5.35%	USD 2.99	2026-07-14
1 month	+35.41%	USD 2.09	2026-06-18
3 month	+106.57%	USD 1.37	2026-04-22
Year to date	+188.01%	USD 0.98	2025-12-31
1 year	+146.09%	USD 1.15	2025-07-21
3 year	-36.55%	USD 4.46	2023-07-21
5 year	-96.71%	USD 85.96	2021-07-22
Since inception	-57.25%	USD 6.62	2013-10-01

Fate Therapeutics Financials at a Glance

Market Cap

$329.86M

Revenue (TTM)

$6.32M

Net Income (TTM)

-$129.91M

EPS (TTM)

-$1.09

P/E Ratio

-2.60

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$2.58

Volume

1,499,137.076

Open

$2.80

Price

$2.58

Volume

1,499,137.076

Open

$2.80

Previous Close

$2.58

Daily Range

$2.57 - $2.82

52-Week Range

$0.91 - $3.23

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$2.58

Volume

1,499,137.076

Open

$2.80

Previous Close

$2.58

Daily Range

$2.57 - $2.82

52-Week Range

$0.91 - $3.23

Estimated Earnings Date

Aug 11, 2026

FATE News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fate Therapeutics

Fate makes ready-to-use cell therapies to treat cancer and immune diseases. These treatments help patients by using engineered cells to attack sick cells. The company aims to make advanced medicine more accessible and easier to receive.

The Fighting Cell Lineup

CAR T-cell Programs: FT819 and FT836 treatments using T-cells engineered with chimeric antigen receptors (CAR) to target specific proteins on cancer or autoimmune cells.
CAR NK Programs: FT522 treatments using natural killer (NK) cells designed to function without the need for harsh preparation chemotherapy.
Solid Tumor Candidates: FT825 and FT836 products specifically built to find and destroy tumors in organs like the colon or breast.
iPSC Platform: A technology using induced pluripotent stem cells to create a steady supply of identical, mass-produced therapeutic cells.

Big Deals and New Trials

Collaborated with Ono Pharmaceutical in 2018 to develop cancer treatments, with expansion amendments through June 2025.
Launched a Phase 1 study for FT825 in January 2024 to treat patients with advanced solid tumors.
Obtained RMAT (Regenerative Medicine Advanced Therapy) designation for FT819 from the FDA in April 2025 to speed up regulatory review.
Secured $11.9 million in total awards from the California Institute for Regenerative Medicine (CIRM) during 2024 and 2025 for clinical research.
Expanded clinical testing for FT819 to the U.K. and EU in late 2025 for patients with systemic lupus erythematosus (SLE).

What Makes Fate Different?

Fate uses a master cell line system to produce uniform treatments at scale. Its Sword and Shield technology aims to let patients receive cell therapy as outpatients without staying in the hospital.

A Look at the Numbers

Net income narrowed to -$32.4 million in Q4 2025, improving 37.9% from the previous year.
Revenue reached $1.4 million in Q4 2025, down 26.4% year-over-year.
Operating losses improved by 43.8% to reach -$34.7 million in Q4 2025.
Free cash flow was -$24.5 million in Q4 2025, narrowing by 12.2% from Q4 2024.

Bottom Line

Fate has transitioned from early research to testing multiple mass-producible cell therapies in human trials. Its focus on ready-to-use products and hospital-free delivery marks a shift toward making advanced biologics more accessible.

AI Generated • May 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

161

CEO

Bahram Valamehr, PhD, MBA

Website

www.fatetherapeutics.com

Headquarters

San Diego, CA 92131, US

FATE Financials

Key Financial Metrics (TTM)

Gross Margin

-415.79%

Operating Margin

-2207.47%

Net Income Margin

-2056.79%

Return on Equity

-58.89%

Return on Capital

-51.82%

Return on Assets

-45.59%

Earnings Yield

-38.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$329.86M

Shares Outstanding

116.56M

Volume

1.50M

Avg. Volume

4.12M

Financials (TTM)

Gross Profit

-$26.26M

Operating Income

-$139.42M

EBITDA

-$117.42M

Operating Cash Flow

-$103.10M

Capital Expenditure

-$5.00M

Free Cash Flow

-$108.09M

Cash & ST Invst.

$174.82M

Total Debt

$76.79M

Fate Therapeutics Performance Analysis

Fate Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 96,300,000	72.4%
2023	2023-12-31	USD 63,533,000	-34.0%
2024	2024-12-31	USD 13,631,000	-78.5%
2025	2025-12-31	USD 6,646,000	-51.2%

Fate Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	17.1%
Q3	2025-09-30	-8.7%
Q4	2025-12-31	-21.4%
Q1	2026-03-31	-5.1%

Fate Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.91	29.9%
2023	2023-12-31	USD -1.64	-43.8%
2024	2024-12-31	USD -1.64	0.2%
2025	2025-12-31	USD -1.15	-30.0%

Fate Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	9.4%
Q3	2025-09-30	6.9%
Q4	2025-12-31	N/A
Q1	2026-03-31	3.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.30M

-20.3%

Gross Profit

-$1.62M

+94.1%

Gross Margin

-1.25%

N/A

Market Cap

$329.86M

N/A

Market Cap/Employee

$2.05M

N/A

Employees

161

N/A

Net Income

-$31.21M

+17.0%

EBITDA

-$28.30M

+17.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$174.82M

-27.3%

Total Debt

$76.79M

-7.9%

Accounts Receivable

$704.00K

-70.7%

Inventory

$0.00

N/A

Long Term Debt

$72.05M

-6.2%

Short Term Debt

$4.74M

-27.6%

Return on Assets

-45.59%

N/A

Return on Invested Capital

-54.84%

N/A

Free Cash Flow

-$31.06M

+11.3%

Operating Cash Flow

-$30.82M

+8.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PRLDPrelude Therapeutics Incorporated

PRLDPrelude Therapeutics Incorporated$3.93-2.85%

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.41-6.59%

ALECAlector, Inc.

ALECAlector, Inc.$1.53-0.65%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$3.97-3.41%

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$2.21-0.90%

VORVor Biopharma Inc.

VORVor Biopharma Inc.$19.51-2.69%

PEPGPepGen Inc.

PEPGPepGen Inc.$1.92-9.43%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$23.04+0.04%

ONDSOndas

ONDSOndas$8.00+0.04%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.56+0.20%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.79-0.03%

PATHUiPath

PATHUiPath$10.70-0.11%

NOKNokia

NOKNokia$10.28-0.03%

SOFISoFi Technologies

SOFISoFi Technologies$17.07-0.03%

Questions About FATE

What is the current price of Fate Therapeutics?

Fate Therapeutics is trading at $2.58 per share.

What is the 52-week range for Fate Therapeutics?

Over the past 52 weeks, Fate Therapeutics has traded between $0.91 and $3.23.

How much debt does Fate Therapeutics have?

As of the most recent reporting period, Fate Therapeutics reported total debt of $76.79M.

How much cash does Fate Therapeutics have on hand?

Fate Therapeutics reported $39.57M in cash and cash equivalents in its most recent financial results.

What is Fate Therapeutics’s dividend yield?

Fate Therapeutics does not currently have a dividend yield.

Fate Therapeutics(NASDAQ) FATE

Fate Therapeutics Financials at a Glance

FATE News

3 Cathie Wood Stocks for the Future

Cathie Wood Likes Fate Therapeutics, Should You?

3 Biotech Stocks That Can Double Your Money, According to Wall Street

Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain

Why Fate Therapeutics Stock Is Sliding Today

Did You See What Cathie Wood Bought on Wednesday?

3 of the Most Innovative Stocks to Buy Now

2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Fate Therapeutics

The Fighting Cell Lineup

Big Deals and New Trials

What Makes Fate Different?

A Look at the Numbers

Bottom Line

FATE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Fate Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FATE

What is the current price of Fate Therapeutics?

What is the 52-week range for Fate Therapeutics?

How much debt does Fate Therapeutics have?

How much cash does Fate Therapeutics have on hand?

What is Fate Therapeutics’s dividend yield?

Premium Investing Services